Athersys, Inc. Confirms Completion of Patient Enrollment for Its Phase I Study of MultiStem(R) for Hematopoietic Stem Cell Transplant Support

CLEVELAND, Oct. 17, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced that it has completed patient enrollment of the repeat dose arm of its clinical study involving administration of MultiStem® to patients being treated for leukemia or other blood born cancers. Initial results from the repeat dose arm of this trial will be announced following the completion of patient evaluation periods and subsequent analysis of data around the end of the year.